Xianzhong Ding, MD, PhD CURRICULUM VITAE Address Department of Pathology Saint Louis University School of Medicine Desloge Towers, 4th floor, Room 450 3634 Vista Ave. Saint Louis, MO 63104 Telephone 314-268-7168 (office) 314-577-6132 (fax) Electronic mail [email protected] Licensure Missouri, Illinois Board Certification Anatomic and Clinical Pathology, American Board of Pathology, 2012 Education Creighton University School of Medicine, PhD, 2001 Tongji Medical College, MD, 1994 Postgraduate Training 2012-2013: Fellow in Gastrointestinal pathology, Department of pathology, The Mount Sinai Hospital, Mount Sinai School of Medicine, New York, NY 2008-2012: Resident in Anatomical and Clinical Pathology, Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL Academic Appointment 2001-2008: Research Assistant Professor, Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL 2013-present: Assistant Professor, Department of Pathology, Saint Louis University School of Medicine, Saint Louis, MO Professional Society Affiliations United States and Canadian Academy of Pathology 1

American Society for Clinical Pathology College of American pathologists American Pancreatic Association Awards and Honors 1. Resident Research Forum Award, Chicago Pathology Society and Illinois Registry of Anatomic Pathology, 2010 2. American Cancer Society Young Investigator Award (Principle Investigator), 2005, $87,000 3. Research Award from American Institute for Cancer Research (Co-investigator); 2001-2004, $150,000 4. Pilot research grant, Robert H. Lurie Comprehensive Cancer center, Northwestern University Feinberg School of Medicine (Principle Investigator); 2003 5. Research Award, Lustgarten Foundation for Pancreatic Cancer Research (Coinvestigator), 2001, $250,000 6. Travel Award; American Pancreatic Association; 2000 Peer-Reviewed Publications 1. Melstrom LG, Salabat MR, Ding XZ, Strouch MJ, Grippo PJ, Mirzoeva S, Pelling JC, Bentrem DJ. Apigenin down-regulates the hypoxia response genes: HIF-1α, GLUT-1, and VEGF in human pancreatic cancer cells. J Surg Res. 2011; 167(2):173-81. 2. Ko JH, Kim PS, O'Shaughnessy KD, Ding X, Kuiken TA, Dumanian GA. A quantitative evaluation of gross versus histologic neuroma formation in a rabbit forelimb amputation model: potential implications for the operative treatment and study of neuromas. J Brachial Plex Peripher Nerve Inj. 2011; 6: 8. 3. Roginsky AB, Ding XZ, Woodward C, Ujiki MB, Singh B, Bell RH Jr, Collin P, Adrian TE. Anti-pancreatic cancer effects of a polar extract from the edible sea cucumber, Cucumaria frondosa. Pancreas. 2010; 39(5):646-52. 4. Strouch MJ, Milam BM, Melstrom LG, McGill JJ, Salabat MR, Ujiki MB, Ding XZ, Bentrem DJ. The flavonoid apigenin potentiates the growth inhibitory effects of gemcitabine and abrogates gemcitabine resistance in human pancreatic cancer cells. Pancreas. 2009; 38(4):409-15.

2

5. Sisco M, Kryger ZB, O'Shaughnessy KD, Kim PS, Schultz GS, Ding XZ, Roy NK, Dean NM, Mustoe TA. Antisense inhibition of connective tissue growth factor (CTGF/CCN2) mRNA limits hypertrophic scarring without affecting wound healing in vivo. Wound Repair Regen. 2008; 16(5):661-73. 6. Melstrom LG, Salabat MR, Ding XZ, Milam BM, Strouch M, Pelling JC, Bentrem DJ. Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas. 2008; 37(4):426-31. 7. Melstrom LG, Bentrem DJ, Salabat MR, Kennedy TJ, Ding XZ, Strouch M, Rao SM, Witt RC, Ternent CA, Talamonti MS, Bell RH, Adrian TA. Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clin Cancer Res. 2008; 14(20):6525-30. 8. Li X, Roginsky AB, Ding XZ, Woodward C, Collin P, Newman RA, Bell RH Jr, Adrian TE. Review of the apoptosis pathways in pancreatic cancer and the antiapoptotic effects of the novel sea cucumber compound, Frondoside A. Ann N Y Acad Sci. 2008; 1138:181-98. 9. Hennig R, Osman T, Esposito I, Giese N, Rao SM, Ding XZ, Tong WG, Büchler MW, Yokomizo T, Friess H, Adrian TE. BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation. Br J Cancer. 2008; 99(7):1064-73. 10. Salabat MR, Melstrom LG, Strouch MJ, Ding XZ, Milam BM, Ujiki MB, Chen C, Pelling JC, Rao S, Grippo PJ, McGarry TJ, Bentrem DJ. Geminin is overexpressed in human pancreatic cancer and downregulated by the bioflavanoid apigenin in pancreatic cancer cell lines. Mol Carcinog. 2008; 47(11):835-44. 11. Singh B, Murphy RF, Ding XZ, Roginsky AB, Bell RH Jr, Adrian TE. On the role of transforming growth factor-beta in the growth inhibitory effects of retinoic acid in human pancreatic cancer cells. Mol Cancer. 2007; 6:82. 12. Hennig R, Kehl T, Noor S, Ding XZ, Rao SM, Bergmann F, Fürstenberger G, Büchler MW, Friess H, Krieg P, Adrian TE. 15-lipoxygenase-1 production is lost in pancreatic cancer and overexpression of the gene inhibits tumor cell growth. Neoplasia. 2007; 9(11):917-26. 13. Tong WG, Ding XZ, Talamonti MS, Bell RH, Adrian TE. Leukotriene B4 receptor antagonist LY293111 induces S-phase cell cycle arrest and apoptosis in human pancreatic cancer cells. Anticancer Drugs. 2007; 18(5):535-41. 14. Golkar L, Ding XZ, Ujiki MB, Salabat MR, Kelly DL, Scholtens D, Fought AJ, Bentrem DJ, Talamonti MS, Bell RH, Adrian TE. Resveratrol inhibits pancreatic

3

cancer cell proliferation through transcriptional induction of macrophage inhibitory cytokine-1. J Surg Res. 2007; 138(2):163-9. 15. Ujiki MB, Ding XZ, Salabat MR, Bentrem DJ, Golkar L, Milam B, Talamonti MS, Bell RH Jr, Iwamura T, Adrian TE. Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest. Mol Cancer. 2006; 5:76. 16. Salabat MR, Ding XZ, Flesche JB, Ujiki MB, Robin TP, Talamonti MS, Bell RH Jr, Adrian TE. On the mechanisms of 12-O-tetradecanoylphorbol-13-acetateinduced growth arrest in pancreatic cancer cells. Pancreas. 2006; 33(2):148-55. 17. Ujiki MB, Milam B, Ding XZ, Roginsky AB, Salabat MR, Talamonti MS, Bell RH, Gu W, Silverman RB, Adrian TE. A novel peptide sansalvamide analogue inhibits pancreatic cancer cell growth through G0/G1 cell-cycle arrest. Biochem Biophys Res Commun. 2006; 340(4):1224-8. 18. Tong WG, Ding XZ, Talamonti MS, Bell RH, Adrian TE. LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. Biochem Biophys Res Commun. 2005 Sep; 335(3):949-56. 19. Yoshida S, Ujiki M, Ding XZ, Pelham C, Talamonti MS, Bell RH Jr, Denham W, Adrian TE. Pancreatic stellate cells (PSCs) express cyclooxygenase-2 (COX-2) and pancreatic cancer stimulates COX-2 in PSCs. Mol Cancer. 2005; 4:27. 20. Hennig R, Grippo P, Ding XZ, Rao SM, Buchler MW, Friess H, Talamonti MS, Bell RH, Adrian TE. 5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions. Cancer Res. 2005; 65(14):6011-6. 21. Hennig R, Ventura J, Segersvard R, Ward E, Ding XZ, Rao SM, Jovanovic BD, Iwamura T, Talamonti MS, Bell RH Jr, Adrian TE. LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice. Neoplasia. 2005; 7(4):417-25. 22. Liu S, Gu W, Lo D, Ding XZ, Ujiki M, Adrian TE, Soff GA, Silverman RB.Nmethylsansalvamide a peptide analogues. Potent new antitumor agents. J Med Chem. 2005; 48(10): 3630-8. 23. Oh NG, Son GM, Sin JY, Ding XZ, Adrian TE. Time-course of morphologic changes and peptide YY adaptation in ileal mucosa after loop ileostomy in humans. Dis Colon Rectum. 2005; 48(6):1287-94. 24. Chan CY, Salabat MR, Ding XZ, Kelly DL, Talamonti MS, Bell RH Jr, Adrian TE. Identification and in silico characterization of a novel gene: TPA induced trans-membrane protein. Biochem Biophys Res Commun. 2005; 329(2):755-64.

4

25. Li X, Ding X, Adrian TE. Arsenic trioxide causes redistribution of cell cycle, caspase activation, and GADD expression in human colonic, breast, and pancreatic cancer cells. Cancer Invest. 2004; 22(3):389-400. 26. Yoshida S, Yokota T, Ujiki M, Ding XZ, Pelham C, Adrian TE, Talamonti MS, Bell RH Jr, Denham W. Pancreatic cancer stimulates pancreatic stellate cell proliferation and TIMP-1 production through the MAP kinase pathway. Biochem Biophys Res Commun. 2004; 323(4):1241-5. 27. Hennig R, Ding XZ, Tong WG, Witt RC, Jovanovic BD, Adrian TE. Effect of LY293111 in combination with gemcitabine in colonic cancer. Cancer Lett. 2004; 210(1):41-6. 28. Ding XZ, Tong WG, Adrian TE. Multiple signal pathways are involved in the mitogenic effect of 5(S)-HETE in human pancreatic cancer. Oncology. 2003; 65(4):285-94. 29. Dong ML, Ding XZ, Adrian TE. Red oil A5 inhibits proliferation and induces apoptosis in pancreatic cancer cells. World J Gastroenterol. 2004;10(1):105-11. 30. Li X, Ding X, Adrian TE. Arsenic trioxide induces apoptosis in pancreatic cancer cells via changes in cell cycle, caspase activation, and GADD expression. Pancreas. 2003; 27(2):174-9. 31. Brand RE, Ding XZ, Young CM, Adrian TE. The specificity of amylin for the diagnosis of pancreatic adenocarcinoma. Int J Gastrointest Cancer. 2002; 31(13):123-8. 32. Tong WG, Ding XZ, Witt RC, Adrian TE. Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Mol Cancer Ther. 2002; 1(11):929-35. 33. Ding XZ, Adrian TE. Resveratrol inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Pancreas. 2002; 25(4):e71-6. 34. Tong WG, Ding XZ, Hennig R, Witt RC, Standop J, Pour PM, Adrian TE. Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Clin Cancer Res. 2002; 8(10):323242. 35. Tong WG, Ding XZ, Adrian TE. The mechanisms of lipoxygenase inhibitorinduced apoptosis in human breast cancer cells. Biochem Biophys Res Commun. 2002; 296(4):942-8. 36. Li X, Ding X, Adrian TE. Arsenic trioxide inhibits proliferation and induces apoptosis in pancreatic cancer cells. Anticancer Res. 2002; 22(4):2205-13.

5

37. Hennig R, Ding XZ, Tong WG, Schneider MB, Standop J, Friess H, Büchler MW, Pour PM, Adrian TE. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol. 2002; 161(2):421-8. 38. Ding XZ, Tong WG, Adrian TE. 12-lipoxygenase metabolite 12(S)-HETE stimulates human pancreatic cancer cell proliferation via protein tyrosine phosphorylation and ERK activation. Int J Cancer. 2001; 94(5):630-6. 39. Schmied BM, Ulrich A, Matsuzaki H, Ding X, Ricordi C, Weide L, Moyer MP, Batra SK, Adrian TE, Pour PM. Transdifferentiation of human islet cells in a long-term culture. Pancreas. 2001; 23(2):157-71. 40. Ding XZ, Adrian TE. MEK/ERK-mediated proliferation is negatively regulated by P38 map kinase in the human pancreatic cancer cell line, PANC-1. Biochem Biophys Res Commun. 2001; 282(2):447-53. 41. Schmied BM, Ulrich A, Matsuzaki H, Ding X, Ricordi C, Moyer MP, Batra SK, Adrian TE, Pour PM. Maintenance of human islets in long-term culture. Differentiation. 2000; 66(4-5):173-80. 42. Schneider MB, Matsuzaki H, Haorah J, Ulrich A, Standop J, Ding XZ, Adrian TE, Pour PM. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology. 2001; 120(5):1263-70. 43. Arnelo U, Herrington MK, Theodorsson E, Adrian TE, Reidelberger R, Larsson J, Marcusson J, Strömmer L, Ding X, Permert J. Effects of long-term infusion of anorexic concentrations of islet amyloid polypeptide on neurotransmitters and neuropeptides in rat brain. Brain Res. 2000; 887(2):391-8. 44. Ding XZ, Fehsenfeld DM, Murphy LO, Permert J, Adrian TE. Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression. Pancreas. 2000; 21(3):310-20. 45. Ding XZ, Tong WG, Adrian TE. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res. 2000; 20(4):2625-31. 46. Schmied BM, Ulrich AB, Matsuzaki H, El-Metwally TH, Ding X, Fernandes ME, Adrian TE, Chaney WG, Batra SK, Pour PM. Biologic instability of pancreatic cancer xenografts in the nude mouse. Carcinogenesis. 2000; 21(6):1121-7. 47. Ding XZ, Kuszynski CA, El-Metwally TH, Adrian TE. Lipoxygenase inhibition induced apoptosis, morphological changes, and carbonic anhydrase expression in

6

human pancreatic cancer cells. Biochem Biophys Res Commun. 1999; 266(2):392-9. 48. Ding XZ, Iversen P, Cluck MW, Knezetic JA, Adrian TE. Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochem Biophys Res Commun. 1999; 261(1):218-23. 49. Wang F, Adrian TE, Westermark GT, Ding X, Gasslander T, Permert J. Islet amyloid polypeptide tonally inhibits beta-, alpha-, and delta-cell secretion in isolated rat pancreatic islets. Am J Physiol. 1999; 276(1 Pt 1):E19-24. 50. Fagan SP, Azizzadeh A, Moldovan S, Ray MK, Adrian TE, Ding X, Coy DH, Brunicardi FC. Insulin secretion is inhibited by the subtype five somatostatin receptor in the mouse. Surgery. 1998; 124(2):254-8. 51. Ding X, Flatt PR, Permert J, Adrian TE. Pancreatic cancer cells selectively stimulate islet beta cells to secrete amylin. Gastroenterology. 1998; 114(1):130-8. Review Articles and Book Chapters 1. Ding XZ, Adrian TE. Role of Lipoxygenase Pathways in the Regulation of Pancreatic Cancer Cell Proliferation and Survival. Inflammopharmacology. 2001, 9: 157-164. 2. Ding XZ, Tong WG, Adrian TE. Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer. Pancreatology. 2001; 1(4):291-9. 3. Hennig R, Ding XZ, Tong WG, Adrian TE. Arachidonic acid pathways as targets for pancreatic cancer therapy. Controversies in Pancreatology. Solvay Press, 2002. 4. Ding XZ, Hennig R, Adrian TE. Lipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancer. Mol Cancer. 2003; 2:10. 5. Kennedy TJ, Chan CY, Ding XZ, Adrian TE. Lipoxygenase inhibitors for the treatment of pancreatic cancer. Expert Rev Anticancer Therapy 2003; 3(4): 89-100. 6. Hennig R, Ding XZ, Adrian TE. On the role of the islets of Langerhans in pancreatic cancer. Histol Histopathol. 2004; 19(3):999-1011. 7. Roginsky AB, Ujiki MB, Ding XZ, Adrian TE. On the potential use of flavonoids in the treatment and prevention of pancreatic cancer. In Vivo. 2005;19(1):61-7.

7

8. Melstrom LG, Ding XZ, Adrian TE. Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia. Histol Histopathol. 2007; 22(7):805-14. 9. Mullapudi B, Ding Y, Ding X, Grippo P. Drug Evaulations in Pancreatic Cancer Culture Systems. In: Grippo P, Han H, editors. 2010. Drug Discovery in Pancreatic Cancer. New York: Springer 297. Presentations and Published Abstracts 1. Poster presentation, 2012 annual meeting, United State and Canadian Academy of Pathology, Vancouver. 2. Poster presentation, 2011 annual meeting, United State and Canadian Academy of Pathology, San Antonio. 3. Platform presentation, 2010 annual meeting, United State and Canadian Academy of Pathologist, Washington D.C., March 2010. 4. Case presentation, Illinois Registry of Anatomic Pathology, Chicago, IL. October 2009. 5. Salabat MR, Ding X et al. Upregulation Of Stanniocalcin-1 in Pancreatic Cancer. Gastroenterology 2005; 124(4S2): A532. 6. Chan CY, Burley U, Ding XZ, Talamonti MS, Bell RH, Adrian TE. SPROUTY-2 expression in human pancreatic cancer cells and characterization of the SPROUTY-2 promoter. Pancreas 2004; 29(4): 335. 7. Hennig R, Ding XZ, Tong WG, Yokomizo T, Buchler MW, Freiss H, Rao SM, Talamonti MS, Bell RH, Adrian TE. The leokotriene receptor: BLT2R is overexpressed in pancreatic intraepithelial neoplastic lesion (PanINS): A new target for therapy? Pancreas 2004; 29(4): 336. 8. Segervard R, Hennig R, Ding XZ, Rao S, Permert J, Adrian TE. The influence of obesity on acute experimental pancreatitis is unrelated to systemic inflammation, cyclooxygenase-2 or 5-lipoxygenase expression. Pancreatology 2004; 4: 178. 9. Grippo PJ, Hennig R, Ding XZ, Rao MS, Adrian TE. Overexpression of 5-LOX and COX-2 in early neoplastic lesions from EL-Kras transgenic mice. Proceedings of the American Association for Cancer Research. 2003; 44: 955. 10. Ding XZ, Hennig R, Tong WG, Adrian TE. An LTB4 receptor antagonist, LY293111 blocks pancreatic cancer growth through induction of senescence and G2/M arrest in pancreatic cancer cells. Eicosanoids & Other Bioactive lipids in Cancer, Inflammation and Related Diseases. 8th International Conference, Chicago. 2003.

8

11. Ding XZ, Hennig R, Chan CY, Dong ML, Adrian TE. Upregulated NFAT3 mediated pancreatic cancer cell proliferation. Pancreas 2003; 27(4): 377. 12. Ding XZ, Hennig R, Chan CY, Dong ML, Adrian TE. An LTB4 receptor antagonist, LY293111induces senescence and G2/M arrest in pancreatic cancer cells. Pancreas 2003; 27(4): 377 13. Kennedy TJ, Ding XZ, Bell RH. Evidence for stem cell origin of human pancreatic cancer. Gastroenterology 2003, 124(4, supp): A350.

9